Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 20% Improvement Relative Risk Bowen et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 4,631 patients in the USA (March 2020 - March 2021) Lower mortality with HCQ (p=0.0069) Bowen et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac436 Favors HCQ Favors control
Reduction in risk of death among patients admitted with COVID-19 between first and second epidemic waves in New York City
Bowen et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac436
Bowen et al., Reduction in risk of death among patients admitted with COVID-19 between first and second epidemic waves in.., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac436
Aug 2022   Source   PDF  
  All Studies   Meta
Retrospective 4,631 hospitalized patients in New York, showing higher mortality with remdesivir, and lower mortality with HCQ. Authors suggest that increased mortality during the first epidemic wave was partly due to strain on hospital resources.
risk of death, 20.0% lower, HR 0.80, p = 0.007, treatment 1,317, control 3,314, Table S2, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bowen et al., 25 Aug 2022, retrospective, USA, peer-reviewed, 10 authors, study period 1 March, 2020 - 31 March, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: 1 Reduction in risk of death among patients admitted with COVID-19 between first and 2 second epidemic waves in New York City 3 26 Running Title: Epidemic wave impacts COVID-19 mortality 1 M A N Corresponding Author: Anthony Bowen, MD, PhD 622 West 168th Street 8th Floor, New York, NY, USA 260-403-6964 EP TE D Alternate Jason Zucker, MD, MS 622 West 168th Street 8th Floor, New York, NY, USA 201-723-6637 CC Keywords: COVID-19, Mortality, Cox regression, Epidemics A 29 U Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, USA. 2 Gertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, USA. * Contributed equally 27 28 SC RI PT Anthony Bowen1,*, Jason Zucker1,*, Yanhan Shen2, Simian Huang1, Qiheng Yan2, Medini K. Annavajhala1, Anne-Catrin Uhlemann1, Louise Kuhn2, Magdalena Sobieszczyk1,*, Delivette Castor1,* © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercialNoDerivs licence (, which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact 1 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 1 Abstract 2 4 the emergence of SARS-CoV-2 with heterogeneous differences in mortality. Elucidating factors 5 differentially associated with mortality between epidemic waves may inform clinical and public 6 health strategies. 7 Methods: We examined clinical and demographic data among patients admitted with COVID-19 8 during the first (March-August 2020) and second (August 2020-March 2021) epidemic waves at 9 an academic medical center in New York City. 10 Results: Hospitalized patients (N=4631) had lower overall and 30-day in-hospital mortality, 11 defined as death or discharge to hospice, during the second wave (14% and 11%) than the first 12 (22% and 21%). The wave 2 in-hospital mortality decrease persisted after adjusting for several 13 potential confounders. Adjusting for the volume of COVID-19 admissions, a measure of health 14 system strain, accounted for the mortality difference between waves. Several demographic and 15 clinical patient factors were associated with an increased risk of mortality independent of wave; 16 SARS-CoV-2 cycle threshold, Do-Not-Intubate status, oxygen requirement, and intensive care 17 unit admission. 18 Conclusions: This work suggests that increased in-hospital mortality rates observed during the U N A M D TE EP CC 19 SC RI PT Background: Many regions have experienced successive epidemic waves of COVID-19 since first epidemic wave were partly due to strain on hospital resources. Preparations for future epidemics should prioritize evidence-based patient risks, treatment paradigms, and approaches to 21 augment hospital capacity. A 20 2
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop